Gilead Sciences (GILD) Intangibles (2009 - 2026)
Gilead Sciences' (GILD) quarterly Intangibles came in at $14.0 billion in Q2 2026, down 24.42% on a YoY basis from $18.6 billion in Q2 2025, and down 14.35% quarter-over-quarter from $16.4 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Intangibles for 18 consecutive years, with $14.0 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Intangibles fell 24.42% year-over-year to $14.0 billion; the trailing twelve-month figure through Jun 2026 stood at $14.0 billion (down 24.42% YoY), and the FY2025 full-year result was $17.0 billion, down 14.89% from the prior year.
- Intangibles declined to $14.0 billion in Q2 2026 per GILD's latest filing, from $16.4 billion in the prior quarter.
- Across five years, Intangibles topped out at $30.3 billion in Q1 2022 and bottomed at $14.0 billion in Q2 2026.
- Historically, Intangibles has averaged $23.2 billion across 5 years, with a median of $23.1 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Intangibles dropped 6.54% in 2023, then declined 24.59% in 2024.
- Over 5 years, Intangibles stood at $28.9 billion in 2022, then slipped by 8.44% to $26.5 billion in 2023, then fell by 24.59% to $19.9 billion in 2024, then retreated by 14.89% to $17.0 billion in 2025, then dropped by 17.35% to $14.0 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $14.0 billion, $16.4 billion, and $17.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 93.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.03 Bn |
| Mar 31, 2026 | 16.38 Bn |
| Dec 31, 2025 | 16.98 Bn |
| Sep 30, 2025 | 17.97 Bn |
| Jun 30, 2025 | 18.57 Bn |
| Mar 31, 2025 | 19.36 Bn |
| Dec 31, 2024 | 19.95 Bn |
| Sep 30, 2024 | 20.55 Bn |
| Jun 30, 2024 | 22.83 Bn |
| Mar 31, 2024 | 23.43 Bn |
| Dec 31, 2023 | 26.45 Bn |
| Sep 30, 2023 | 27.15 Bn |
| Jun 30, 2023 | 27.75 Bn |
| Mar 31, 2023 | 28.35 Bn |
| Dec 31, 2022 | 28.89 Bn |
| Sep 30, 2022 | 29.44 Bn |
| Jun 30, 2022 | 29.89 Bn |
| Mar 31, 2022 | 30.33 Bn |
| Dec 31, 2021 | 33.46 Bn |
| Sep 30, 2021 | 33.90 Bn |